As recently as December 10, 2025, Rezolute was a Wall Street darling. Eight analysts rated the stock a Buy, with price targets as high as $17. Its lead drug ersodetug, a monoclonal antibody, had earned two FDA Breakthrough Therapy Designations and the agency had signaled that its Phase 3 trial could support a BLA filing.…
